Last reviewed · How we verify

NCT05454878

Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy

Status unknown Last updated 12 July 2022
What this trial tests

trial in Atrial Fibrillation in 100 participants. Status unknown.

Timeline
15 July 2022
Primary endpoint
1 July 2023
1 December 2023

Quick facts

Lead sponsorChinese PLA General Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date15 July 2022
Primary completion1 July 2023
Estimated completion1 December 2023
Sites1 location across China

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective cohort study is to investigate the incidence of atrial fibrillation after chemotherapy by aplying wearable ECG recoder and the risk factors on patients with newly diagonsed lymphoma

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05454878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing